<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4601616</article-id><article-id pub-id-type="publisher-id">1470-7330-15-S1-O15</article-id><article-id pub-id-type="doi">10.1186/1470-7330-15-S1-O15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>PET/CT imaging in prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Barwick</surname><given-names>Tara</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Imperial College Healthcare NHS Trust and Imperial College, Division of Surgery and Cancer, UK</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>2</day><month>10</month><year>2015</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 15th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens Healthcare GmbH.</named-content></supplement><fpage>O15</fpage><lpage>O15</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Barwick</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Barwick</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/15/S1/O15"/><conference><conf-date>5-7 October 2015</conf-date><conf-name>International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015)</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title/><p>Prostate cancer is the second most common male malignancy worldwide with a wide spectrum of biological behaviour ranging from fairly indolent disease to highly aggressive metastatic castrate resistant tumours. In the past decade there have been advances in therapies for treating advanced and recurrent prostate cancer and improved diagnostic/prognostic tools are required to refine the therapeutic approach at various stages in the management of prostate cancer patients.</p><p>For tumour staging/lesion localisation multiparametric prostate MRI is the modality of choice. Several PET tracers are proving more sensitive than conventional imaging techniques for early detection of lymph node and bone metastases. However a general limitation of PET is the spatial resolution which limits the reliability for detection of small lesions.</p><p>The use of F-18 fluoro-deoxyglucose (FDG) PET/CT in prostate cancer has been disappointing largely due to the fact that many prostate cancers have only low level glucose metabolism.</p><p>C-11/F-18 choline, markers of cell membrane metabolism, are now widely used in Europe and in certain UK centres particularly in the scenario of biochemical relapse and high risk staging with equivocal findings on conventional work-up [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. However, in cases of biochemical relapse with low PSA rise and low PSA velocity, choline PET has low detection rates [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Prostate specific membrane antigen (PSMA), a cell surface membrane glycoprotein, is a promising target for the diagnosis and treatment of prostate cancer. Recently Ga-68 radiolabelled ligand targeted to PSMA has been introduced to a few European centres. Early data suggests this may be more sensitive than choline PET/CT in patients with biochemical failure and low PSA [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. In addition it offers the opportunity for Lu-177 or Y-90 targeted radionuclide therapy.</p><p>F-18 sodium fluoride (NaF) is highly sensitive compared to bone scintigraphy with Tc99m labelled phosphates but only assess skeletal disease [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Other PET tracers being explored include C-11 acetate targeting lipogenesis, tracers radiolabelling bombesin and targeting gastrin-releasing peptide receptor (GRPR), amino acid transport with anti-1-amino-3-F18-fluorocyclobutane-1-carboxylic acid (FACBC ) and F-18-fluoro-5&#x003b1;-dihydrotestosterone (FDHT) targeting the androgen receptor [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>This talk reviews the diagnostic utility of PET in prostate cancer.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Contractor</surname><given-names>K</given-names></name><name><surname>Challapalli</surname><given-names>A</given-names></name><name><surname>Barwick</surname><given-names>T</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Hellawell</surname><given-names>G</given-names></name><name><surname>Hazell</surname><given-names>S</given-names></name><etal/><article-title>Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><issue>24</issue><fpage>7673</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2048</pub-id><pub-id pub-id-type="pmid">22038995</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Umbehr</surname><given-names>MH</given-names></name><name><surname>Muntener</surname><given-names>M</given-names></name><name><surname>Hany</surname><given-names>T</given-names></name><name><surname>Sulser</surname><given-names>T</given-names></name><name><surname>Bachmann</surname><given-names>LM</given-names></name><article-title>The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis</article-title><source>Eur Urol</source><year>2013</year><volume>64</volume><issue>1</issue><fpage>106</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.04.019</pub-id><pub-id pub-id-type="pmid">23628493</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Evangelista</surname><given-names>L</given-names></name><name><surname>Guttilla</surname><given-names>A</given-names></name><name><surname>Zattoni</surname><given-names>F</given-names></name><name><surname>Muzzio</surname><given-names>PC</given-names></name><name><surname>Zattoni</surname><given-names>F</given-names></name><article-title>Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis</article-title><source>Eur Urol</source><year>2013</year><volume>63</volume><issue>6</issue><fpage>1040</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.09.039</pub-id><pub-id pub-id-type="pmid">23036576</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Marzola</surname><given-names>MC</given-names></name><name><surname>Chondrogiannis</surname><given-names>S</given-names></name><name><surname>Ferretti</surname><given-names>A</given-names></name><name><surname>Grassetto</surname><given-names>G</given-names></name><name><surname>Rampin</surname><given-names>L</given-names></name><name><surname>Massaro</surname><given-names>A</given-names></name><etal/><article-title>Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution</article-title><source>Clin Nucl Med</source><year>2013</year><volume>38</volume><issue>1</issue><fpage>e26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/RLU.0b013e318266cc38</pub-id><pub-id pub-id-type="pmid">23242060</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Afshar-Oromieh</surname><given-names>A</given-names></name><name><surname>Zechmann</surname><given-names>CM</given-names></name><name><surname>Malcher</surname><given-names>A</given-names></name><name><surname>Eder</surname><given-names>M</given-names></name><name><surname>Eisenhut</surname><given-names>M</given-names></name><name><surname>Linhart</surname><given-names>HG</given-names></name><etal/><article-title>Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2014</year><volume>41</volume><issue>1</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00259-013-2525-5</pub-id><pub-id pub-id-type="pmid">24072344</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="other"><name><surname>Morigi</surname><given-names>JJ</given-names></name><name><surname>Stricker</surname><given-names>P</given-names></name><name><surname>Van</surname><given-names>LP</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>Q</given-names></name><etal/><article-title>Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy.LID - jnumed.115.160382 [pii]</article-title><source>J Nucl Med</source><year>2015</year><comment>pii : jnumed 115 160382 2015, ii</comment></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Eiber</surname><given-names>M</given-names></name><name><surname>Maurer</surname><given-names>T</given-names></name><name><surname>Souvatzoglou</surname><given-names>M</given-names></name><name><surname>Beer</surname><given-names>AJ</given-names></name><name><surname>Ruffani</surname><given-names>A</given-names></name><name><surname>Haller</surname><given-names>B</given-names></name><etal/><article-title>Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy</article-title><source>J Nucl Med</source><year>2015</year><volume>56</volume><issue>5</issue><fpage>668</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.2967/jnumed.115.154153</pub-id><pub-id pub-id-type="pmid">25791990</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Poulsen</surname><given-names>MH</given-names></name><name><surname>Petersen</surname><given-names>H</given-names></name><name><surname>Hoilund-Carlsen</surname><given-names>PF</given-names></name><name><surname>Jakobsen</surname><given-names>JS</given-names></name><name><surname>Gerke</surname><given-names>O</given-names></name><name><surname>Karstoft</surname><given-names>J</given-names></name><etal/><article-title>Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT</article-title><source>BJU Int</source><year>2014</year><volume>114</volume><issue>6</issue><fpage>818</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/bju.12599</pub-id><pub-id pub-id-type="pmid">24314065</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Jadvar</surname><given-names>H</given-names></name><article-title>Molecular imaging of prostate cancer with PET</article-title><source>J Nucl Med</source><year>2013</year><volume>54</volume><issue>10</issue><fpage>1685</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2967/jnumed.113.126094</pub-id><pub-id pub-id-type="pmid">24084704</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>CY</given-names></name><name><surname>Desai</surname><given-names>B</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Jadvar</surname><given-names>H</given-names></name><article-title>Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature</article-title><source>Am J Nucl Med Mol Imaging</source><year>2014</year><volume>4</volume><issue>6</issue><fpage>580</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">25250207</pub-id></mixed-citation></ref></ref-list></back></article>